Medtronic, Inc. Resolute® Stent Shows Strong Performance in Heart Disease Patients With and Without Diabetes

Published: May 25, 2012

MINNEAPOLIS--(BUSINESS WIRE)--According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, the Resolute® drug-eluting stent (DES) from Medtronic, Inc. (NYSE:MDT) yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up.

Back to news